Table 2.
Summary of clinical information of the study cohorts (control cortex, control hippocampus, TLE-HS, FCD Iia, FCD Iib, and TSC cortical tubers)
| Mean age at onset of epilepsy (years) | Mean age surgery (years) | Average seizure frequency (months) | Mutation | Medications | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DEPDC5 | AKT3 | MTOR | NLPR2/NLPR3 | TSC1 | TSC2 | 1 | 2 | ≥3 | ||||
|
Control Cortex (n = 14) |
21 (0–61) |
|||||||||||
| Control Hippocampus (n = 13) |
47 (0–82) |
|||||||||||
|
TLE-HS (n = 64) |
12 (0–48) |
35 (2–62) |
24 | 13 | 32 | 19 | ||||||
|
FCD IIa (n = 17) |
5 (0–22) |
11 (0–34) |
356 | 4 | 3 | 4 | 2 | 1 | 3 | 13 | ||
|
FCD IIb (n = 33) |
4 (0–21) |
15 (2–46) |
208 | 10 | 1 | 4 | 11 | 18 | ||||
|
TSC cortical tubers (n = 21) |
3 (0–26) |
7 (0–30) |
148 | 6 | 15 | 3 | 6 | 12 | ||||
For detailed information please refer to Supplementary Data 9.
FCD focal cortical dysplasia, TLE-HS temporal lobe epilepsy with hippocampal sclerosis, TSC tuberous sclerosis complex.